The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Mylan Receives U.S. Approval for HIV/AIDS Treatment

September 22, 2011

Canonsburg, Pa.-based Mylan Inc. said Tuesday it has received tentative US approval for a generic version of an HIV treatment regimen. Included in the regimen are generic versions of GlaxoSmithKline PLC's Epivir (lamivudine), Gilead Sciences Inc.'s Viread (tenofovir), and Boehringer Ingelheim's Viramune (nevirapine). Mylan said its subsidiary, Matrix Laboratories Ltd., received clearance from the Food and Drug Administration through the President's Emergency Plan for AIDS Relief. Eligible for sale outside the United States, the regimen will be offered in some developing nations.

Back to other news for September 2011

Adapted from:
Associated Press

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
More on Generic/Discount HIV Drug Access in the Developing World

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: